期刊文献+

盐酸伊立替康在宫颈癌顺铂方案化疗治疗中的应用效果 被引量:12

Clinical Efficacy of Irinotecan Hydrochloride in Cisplatin Chemotherapy for Cervical Cancer
下载PDF
导出
摘要 目的探讨盐酸伊立替康在宫颈癌顺铂方案化疗治疗中的应用效果。方法按照化疗方案不同将105例ⅠB~ⅡB期宫颈癌患者均分为实验组63例和对照组42例,实验组患者采取盐酸伊立替康联合顺铂方案化疗后行手术治疗,对照组患者仅采取顺铂方案化疗后行手术治疗,比较2组治疗效果。结果实验组患者RR率和手术实施率均明显高于对照组,差异具有统计学意义(P〈0.05);2组患者化疗期间不良反应发生率比较,差异无统计学意义(P〉0.05);实验组患者手术时间、术中出血量及并发症发生率均明显低于对照组,差异具有统计学意义(P〈0.05);实验组患者宫颈深肌层浸润、宫旁浸润、盆腔淋巴结转移、阴道切缘阳性和脉管癌栓发生率均明显低于对照组,差异具有统计学意义(P〈0.05)。结论盐酸伊立替康能够有效提高顺铂化疗效果,为手术治疗创造有利条件,提高手术质量,降低术后并发症及术后病理高危因素发生率,可作为优选治疗方案。 Objective To explore the clinical efficacy of irinotecan hydrochloride in cisplatin chemotherapy for cervical cancer. Methods 105 cases of patients with ⅠB - ⅡB cervical cancer were divided into the experiment group( 63 cases) and the control group( 42 cases) according to different treatment methods. The experiment group were treated by irinotecan hydrochloride combined with cisplatin,the control group were treated by cisplatin. The clinical effects were compared between the 2 groups.Results The rates of RR and operation implementation of the experiment group were higher than those of the control group( P〈0. 05); There had no significant difference in the rate of toxic reactions( P〉0. 05); The time of operation,intraoperative blood loss,complication of the experiment group were lower than those the control group( P〈0. 05); The rate of deep cervical muscle layer infiltration,parametrial infiltration,pelvic lymph node metastasis,vaginal cut edge positive,vessel carcinoma embolus of the experiment group were lower than those of the control group( P〈0. 05). Conclusion Irinotecan hydrochloride can improve the clinical effects of cisplatin,create favorable conditions for surgical treatment,improve the quality of surgery,reduce the postoperative complications and postoperative pathological risk factors. It can be used as optimal treatment plan.
出处 《实用癌症杂志》 2016年第5期808-810,813,共4页 The Practical Journal of Cancer
关键词 盐酸伊立替康 宫颈癌 顺铂 Irinotecan hydrochloride Cervical cancer Cisplatin
  • 相关文献

参考文献13

二级参考文献34

  • 1Nicholas P Campbell,Victoria M Villaflor.Neoadjuvant treatment of esophageal cancer[J].World Journal of Gastroenterology,2010,16(30):3793-3803. 被引量:17
  • 2王平,彭芝兰,张家文,刘辉,张崇淑,曹泽毅.子宫颈癌新辅助化疗中不同化疗途径的疗效比较[J].中华妇产科杂志,2005,40(4):227-230. 被引量:109
  • 3糜若然,陈星.宫颈癌新辅助化疗的评价[J].国外医学(妇产科学分册),2006,33(1):61-63. 被引量:22
  • 4赵淑萍,王泽华.巨块型宫颈癌Ⅰ_(B2)~Ⅱ_B期68例术前全身新辅助化疗的近期疗效观察[J].中国实用妇科与产科杂志,2006,22(4):271-273. 被引量:22
  • 5Rose PG,AIi S,Watkins E,et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecologic oncology group study [ J ]. J Clin Oncol, 2007,25 ( 19 ) : 2804- 2810.
  • 6Chen H , Liang C, Zhang L, et al. Clinicalefficacy of modified preoperative neoadjuvant chemotherapy in the treatment of |o- cally advanced ( stage IB2 to IIB) cervical cancer:random- ized study [ J ]. Gynecol Oncol,2008,110 ( 3 ) : 308.
  • 7Therasse P, Arbuck SG, Eisenhauer EA, et al. New guiddIines to evaluate the response to treatment in solid[J]. JNCI, 2000,92 : 205.
  • 8Rose PG. IcaUy advanced cervical cancer[ J]. Current Opin- ion Obstet Gynecol ,2001,13 ( 1 ) :65.
  • 9Sultana H, Kigawa J, Kanamori Y, et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uteri- necervical cancer [ J ]. Ann Oncol, 2003,14 ( 2 ) : 214.
  • 10Reuter S. Neoadjuvant chemotherapy timing crucial in cervi- cal cancer[ J ] Eur Cancer, 2003,39 ( 19 ) : 2470.

共引文献252

同被引文献94

引证文献12

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部